Stockreport

Should Brepocitinib's New Trials and Batoclimab's Setback Require Action From Roivant Sciences (ROIV) Investors? [Yahoo! Finance]

Roivant Sciences Ltd.  (ROIV) 
PDF eye disease, while also announcing that Priovant has begun a new seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, alongside ongoing late-stage programs [Read more]